January 2025, Vol 15, No 1

The Calendar Year 2025 Medicare Physician Fee Schedule Final Rule was published on November 1, 2024. Providers should understand the new regulations and guidelines to stay compliant with billing and coding practices. Read More ›

Billing for navigation services was a central topic at the recently held Academy of Oncology Nurse and Patient Navigators meeting, with one speaker discussing the vital importance of invoicing for these services in light of recent reimbursement obstacles. Read More ›

Adding tafasitamab (Monjuvi; Incyte) to lenalidomide (Revlimid) and rituximab (Rituxan) resulted in a 57% reduction in investigator-assessed risk of progression, relapse, or mortality in patients with relapsed or refractory follicular lymphoma, according to results from the inMIND trial, which were presented at the 66th ASH Annual Meeting and Exposition held in San Diego, CA. Read More ›

Daratumumab (Darzalex Faspro; Johnson & Johnson) use was associated with a 51% reduction in risk of disease progression for patients with smoldering multiple myeloma, when compared with similar patients who were actively monitored but not treated, according to results of a study presented at the 66th ASH Annual Meeting and Exposition held in San Diego, CA. Read More ›

Merck’s investigational antibody–drug conjugate that targets receptor tyrosine kinase–like orphan receptor 1 (ROR1), zilovertamab vedotin, used in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) for the treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) achieved a 100% (n=15) complete response (CR) rate, according to results presented at the 66th ASH Annual Meeting and Exposition, in San Diego, CA, and simultaneously published in Blood. Read More ›

Using cannabis to reduce pain associated with their cancer would be “highly” accepted among patients with multiple myeloma (MM), but more education is needed for oncology providers in discussing its use with these patients, according to results of a survey presented at the 66th ASH Annual Meeting and Exposition held in San Diego, CA Read More ›

The financial burden often accompanying a cancer diagnosis, coupled with consequent unmet health-related social needs like food insecurity (FI), may be associated with increased trips to the emergency department (ED). Ongoing screening of these patients to help identify areas to intervene and, perhaps, reduce these trips is warranted. Read More ›

The first responders who were exposed to high levels of airborne dust, gases, and potential cancer-causing substances at Ground Zero following the 9/11 attacks that destroyed the Twin Towers in New York may now be facing an increased risk of developing leukemia and exhibit a distinct spectrum of precancerous genetic changes, according to data presented at the 66th ASH Annual Meeting and Exposition held in San Diego, CA. Read More ›

Subgroup analyses presented at the American Society of Hematology (ASH) Annual Meeting San Diego support the clinical benefit of brentuximab vedotin (Adcetris; Pfizer) in heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Read More ›

Officials with the FDA have approved durvalumab (Imfinzi; AstraZeneca) for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Read More ›

Zenocutuzumab-zbco (Bizengri; Merus) has been granted accelerated approval for adults with advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy or advanced, unresectable, or metastatic non–small cell lung cancer harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. Read More ›